Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Microencapsulated CYP 2B1-expressing cells + ifosfamide - PharmaCyte Biotech

Next Previous
X
Search
Drug Profile

Microencapsulated CYP 2B1-expressing cells + ifosfamide - PharmaCyte Biotech

Alternative Names: Breast cancer cell therapy - PharmaCyte Biotech; CapCell®; CYP-2B1-gene-therapy-PharmaCyte-Biotech; CypCaps™; Cytochrome-P450-2B1-gene-therapy-PharmaCyte-Biotech; Encapsulated cyclophosphamide-activating cells - PharmaCyte Biotech; Encapsulated ifosfamide-activating cells - PharmaCyte Biotech; Encapsulated-cell-therapy-PharmaCyte-Biotech; Microencapsulated-P450-2B1-expressing-cells-PharmaCyte-Biotech; NovaCaps®; Ovarian cancer cell therapy - PharmaCyte Biotech; P450-2B1-gene-therapy-PharmaCyte-Biotech; Pancreatic cancer cell therapy - PharmaCyte Biotech

Latest Information Update: 28 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic; GSF-National Research Center for Environment and Health
  • Developer Heidelberg Pharma AG; PharmaCyte Biotech; Translational Drug Development
  • Class Analgesics; Antineoplastics; Cyclophosphamides; Gene therapies; Oxazines; Pluripotent stem cell therapies
  • Mechanism of Action Alkylating agents; Cell replacements; Cytochrome P-450 enzyme system stimulants; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Breast cancer; Malignant ascites; Ovarian cancer; Pain

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Malignant-ascites in Germany (Parenteral)
  • 20 Jul 2022 Pharmacodynamics data from preclinical data in Malignant ascites released by PharmaCyte Biotech
  • 19 Apr 2022 Adverse events data from a preclinical trial in Pancreatic cancer released by PharmaCyte

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top